SBP GROUP (01177): TQ-A3334 "TLR7 agonist" Phase II clinical data presented at 2026 AASLD

SBP GROUP (01177) announced that the Phase II clinical study results of TQ-A3334 "TLR7 agonist", a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), were presented in an oral presentation at the Late-Breaking Abstract Parallel Session of the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). TQ-A3334 is a novel, highly selective oral Toll-like receptor 7 (TLR7) agonist. TLR agonists can restore exhausted innate and adaptive immunity and enhance antiviral defense. TQ-A3334 has demonstrated good safety and preliminary anti-hepatitis B virus (HBV) activity in previous clinical studies. This Phase II study was designed to evaluate the efficacy and safety of TQ-A3334 in combination with nucleos(t)ide analogues (NAs) in the treatment of patients with chronic HBV infection.